2024-09-02 - Analysis Report
## Vertex Pharmaceuticals (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals is a global biotechnology company focused on the development and commercialization of therapies for serious diseases.

**Performance Analysis:**

1. **Performance vs. S&P 500:**
    - **Cumulative return:** VRTX: 141.66%, VOO: 89.66%
    - **Outperformance:** VRTX outperformed VOO by 52.0% 
    - **Relative Outperformance:** The current outperformance is positioned at the 91.44 percentile of historical performance relative to VOO.

2. **Recent Price Action:**
    - **Closing Price:** $495.89
    - **5-day Moving Average:** $488.38
    - **20-day Moving Average:** $478.45
    - **60-day Moving Average:** $482.04
    - **Analysis:** The stock price is currently trading above all three moving averages, indicating a potential bullish momentum.

3. **Technical Indicators:**
    - **RSI:** 79.95. The RSI is in overbought territory, indicating potential for a short-term correction.
    - **PPO:** 0.39. The PPO is positive, suggesting a potential uptrend.
    - **Delta_Previous_Relative_Divergence:** -6.98. The negative value indicates a recent decrease in relative outperformance, suggesting a potential short-term decline.
    - **Expected Return:** 5.46%. The projected annualized return over the next 5 years is positive, indicating potential long-term growth.

4. **Recent Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ | 
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

- **Most Recent Earnings (2024-08-02):** The most recent earnings report showed a significant decline in EPS, missing analyst estimates. However, revenue was in line with expectations.

**Summary:**

- VRTX has consistently outperformed the S&P 500 over the long term, currently displaying strong outperformance compared to the index.
- Short-term price action shows bullish momentum, with the stock trading above all moving averages.
- Technical indicators suggest a potential for a short-term correction, although the overall trend remains positive.
- Recent earnings showed a miss on EPS, but revenue was as expected.
- The projected long-term return remains positive, suggesting potential growth for long-term investors.

**Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice. 
